Zobrazeno 1 - 10
of 3 108
pro vyhledávání: '"Pharmacogenetic"'
Publikováno v:
Безопасность и риск фармакотерапии, Vol 12, Iss 2, Pp 132-154 (2024)
INTRODUCTION. Pharmacogenetic (PGx) testing plays a significant role in predicting the risk of adverse drug reactions (ADRs) associated with valproic acid (VPA) products, which are among the most prescribed medicinal products in neurology and psychia
Externí odkaz:
https://doaj.org/article/32c6ea0e49e5483e87a4e211daaad892
Autor:
Julien De Greef, Mathilde Akue, Nadtha Panin, Kévin-Alexandre Delongie, Marina André, Gwenaëlle Mahieu, Emilia Hoste, Laure Elens, Leïla Belkhir, Vincent Haufroid
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Bictegravir, a key second-generation integrase strand transfer inhibitor in the treatment of HIV, is subject to active efflux transport mediated by ABCB1 (P-glycoprotein). Several coding variants of ABCB1 have been described and associated w
Externí odkaz:
https://doaj.org/article/673a1d72024c4c09bb675d1b896f6a08
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-14 (2024)
Abstract Analyze the relationship between genetic variations in the MTHFR gene at SNPs (rs1801131 and rs1801133) and the therapy outcomes for Iraqi patients with rheumatoid arthritis (RA). The study was conducted on a cohort of 95 RA Iraqi patients.
Externí odkaz:
https://doaj.org/article/8d17037d576548e5a3e9790c80e43e6d
Autor:
A. S. Zhiryakova, N. P. Denisenko, A. V. Kryukov, K. A. Akmalova, S. N. Tuchkova, K. B. Mirzaev, D. A. Sychev
Publikováno v:
Безопасность и риск фармакотерапии, Vol 12, Iss 2, Pp 178-189 (2024)
INTRODUCTION. The variability in patient response to non-steroidal anti-inflammatory drugs (NSAIDs) may be due to genetic polymorphisms. Decreased-function or non-functional CYP2C9 alleles are known to be significant contributors to response variabil
Externí odkaz:
https://doaj.org/article/ce69b2b2c49b44658781ec122244b276
Publikováno v:
International Journal of Mycobacteriology, Vol 13, Iss 2, Pp 206-212 (2024)
Background: Pharmacogenetic research has led to significant progress in understanding how genetic factors influence drug response in tuberculosis (TB) treatment. One ongoing challenge is the variable occurrence of adverse drug reactions in some TB pa
Externí odkaz:
https://doaj.org/article/f2b859134d1445a4b3e3e6a1b6b714b3
Autor:
Rita Ioana Platona, Florica Voiță-Mekeres, Cristina Tudoran, Mariana Tudoran, Virgil Radu Enătescu
Publikováno v:
Clinics and Practice, Vol 14, Iss 3, Pp 703-717 (2024)
(1) Background: The aim of this study was to analyze the impact of pharmacogenetic-guided antidepressant therapy on the 12-month evolution of the intensity of depressive symptoms in patients with recurrent depressive disorder (RDD) in comparison to a
Externí odkaz:
https://doaj.org/article/b336844a6c4f4464a3e181e8eb1f7e37
Autor:
Pravdić Zlatko, Suvajdžić-Vuković Nada, Virijević Marijana, Mitrović Mirjana, Pantić Nikola, Sabljić Nikica, Pavlović Đorđe, Marjanović Irena, Bukumirić Zoran, Vidović Ana, Jaković Ljubomir, Pavlović Sonja, Gašić Vladimir
Publikováno v:
Journal of Medical Biochemistry, Vol 43, Iss 4, Pp 545-555 (2024)
Background: Cytarabine-anthracycline-based induction chemotherapy remains the standard of care for remission induction among patients with newly diagnosed acute myeloid leukaemia (AML). There are remarkable differences in therapy response among AML p
Externí odkaz:
https://doaj.org/article/2167caa192c443598359c600cecf6e2a
Publikováno v:
BMC Genomics, Vol 25, Iss 1, Pp 1-8 (2024)
Abstract Here we describe a new public pharmacogenetic (PGx) annotation database of a large (n = 3,202) and diverse biospecimen collection of 1000 Genomes Project cell lines and DNAs. The database is searchable with a user friendly, web-based tool (
Externí odkaz:
https://doaj.org/article/adf3ff494b5142e58db5106d9de347fa
Autor:
Luis Jaramillo‐Valverde, Kelly S. Levano, David D. Tarazona, Silvia Capristano, Cesar Sanchez, Julio A. Poterico, Eduardo Tarazona‐Santos, Heinner Guio
Publikováno v:
Pharmacology Research & Perspectives, Vol 12, Iss 3, Pp n/a-n/a (2024)
Abstract In Peru, 29 292 people were diagnosed with tuberculosis in 2022. Although tuberculosis treatments are effective, 3.4%–13% are associated with significant adverse drug reactions, with drug‐induced liver injury (DILI) considered the most p
Externí odkaz:
https://doaj.org/article/6a2c8efeecdb4ee890ccd209a7038903
Autor:
Florine M. Wiss, Samuel S. Allemann, Henriette E. Meyer zu Schwabedissen, Céline K. Stäuble, Thorsten Mikoteit, Markus L. Lampert
Publikováno v:
Frontiers in Psychiatry, Vol 15 (2024)
Suspected adverse drug reactions (ADRs) during treatment with clozapine often prompt therapeutic drug monitoring (TDM) in clinical practice. Currently, there is no official recommendation for pharmacogenetic (PGx) testing in the context of clozapine
Externí odkaz:
https://doaj.org/article/763b15bacd5e491ca34d86c7e9a7165f